Mice deficient in proglucagon-derived peptides exhibit glucose intolerance on a high-fat diet but are resistant to obesity

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Takagi, Yusuke ^a   Kinoshita, Keita ^a   Ozaki, Nobuaki ^a   Seino, Yusuke ^b   Murata, Yoshiharu ^a   Oshida, Yoshiharu ^a   Hayashi, Yoshitaka ^a  

^a NAGOYA UNIVERSITY   (Japan)

^b NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

LIRAGLUTIDE; MESSENGER RNA; PROGLUCAGON DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; PEPTIDE; PROGLUCAGON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BROWN ADIPOSE TISSUE; CONTROLLED STUDY; DRUG EFFICACY; ENERGY BALANCE; ENERGY EXPENDITURE; ENERGY METABOLISM; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HOMOZYGOSITY; INSULIN RELEASE; INSULIN TOLERANCE TEST; LIPID DIET; MORPHOMETRICS; MOUSE; NONHUMAN; OBESITY; OXYGEN CONSUMPTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SIGNAL TRANSDUCTION; THERMOGENESIS; WEIGHT GAIN; WHITE ADIPOSE TISSUE; ANIMAL; C57BL MOUSE; GLUCOSE TOLERANCE TEST; INSULIN RESISTANCE; MALE; METABOLISM; PANCREAS ISLET BETA CELL; PHYSIOLOGY; PROCEDURES;

ANIMALS; DIET, HIGH-FAT; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; MICE; MICE, INBRED C57BL; OBESITY; PEPTIDES; PROGLUCAGON; WEIGHT GAIN;

EID: 84945940926     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0138322     Document Type: Article

References (43)

1. Li XC, Zhuo JL (2013) Current insights and new perspectives on the roles of hyperglucagonemia in non-insulin-dependent type 2 diabetes. Curr Hypertens Rep 15: 522-530 doi: 10.1007/s11906-013-0383-y
2. Basu A, Alzaid A, Dinneen S, Caumo A, Cobelli C, Rizza RA (1996) Effects of a change in the pattern of insulin delivery on carbohydrate tolerance in diabetic and nondiabetic humans in the presence of differing degrees of insulin resistance. J Clin Invest 97: 2351-2361 PMID: 8636416
3. Butler PC, Rizza RA (1991) Contribution to postprandial hyperglycemia and effect on initial splanchnic glucose clearance of hepatic glucose cycling in glucose-intolerant or NIDDM patients. Diabetes 40: 73-81
4. Larsson H, Ahren B (2000) Islet dysfunction in insulin resistance involves impaired insulin secretion and increased glucagon secretion in postmenopausal women with impaired glucose tolerance. Diabetes Care 23: 650-657
5. Baron AD, Schaeffer L, Shragg P, Kolterman OG (1987) Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes 36: 274-283
6. Shah P, Vella A, Basu A, Basu R, Schwenk WF, Rizza RA (2000) Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 85: 4053-4059
7. Jiang G, Zhang BB (2003) Glucagon and regulation of glucose metabolism. Am J Physiol Endocrinol Metab 284: E671-678
8. Gelling RW, Du XQ, Dichmann DS, Romer J, Huang H, Cui L, et al. (2003) Lower blood glucose, hyperglucagonemia, and pancreatic α cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci U S A 100: 1438-1443
9. Parker JC, Andrews KM, Allen MR, Stock JL, McNeish JD (2002) Glycemic control in mice with targeted disruption of the glucagon receptor gene. Biochem Biophys Res Commun 290: 839-843
10. Johnson DG, Goebel CU, Hruby VJ, Bregman MD, Trivedi D (1982) Hyperglycemia of diabetic rats decreased by a glucagon receptor antagonist. Science 215: 1115-1116 PMID: 6278587
11. Van Tine BA, Azizeh BY, Trivedi D, Phelps JR, Houslay MD, Johnson DG, et al. (1996) Low level cyclic adenosine 3',5'-monophosphate accumulation analysis of [des-His1, des-Phe6, Glu9] glucagon-NH2 identifies glucagon antagonists from weak partial agonists/antagonists. Endocrinology 137: 3316-3322
12. Winzell MS, Brand CL, Wierup N, Sidelmann UG, Sundler F, Nishimura E, et al. (2007) Glucagon receptor antagonism improves islet function in mice with insulin resistance induced by a high-fat diet. Diabetologia 50: 1453-1462
13. Conarello SL, Jiang G, Mu J, Li Z, Woods J, Zycband E, et al. (2007) Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin-mediated β cell loss and hyperglycaemia. Diabetologia 50: 142-150
14. Chatzigeorgiou A, Kandaraki E, Papavassiliou AG, Koutsilieris M (2014) Peripheral targets in obesity treatment: a comprehensive update. Obes Rev
15. Lockie SH, Stefanidis A, Oldfield BJ, Perez-Tilve D (2013) Brown adipose tissue thermogenesis in the resistance to and reversal of obesity: A potential new mechanism contributing to the metabolic benefits of proglucagon-derived peptides. Adipocyte 2: 196-200 doi: 10.4161/adip.25417
16. Lo KA, Sun L (2013) Turning WAT into BAT: a review on regulators controlling the browning of white adipocytes. Biosci Rep 33: e00065 doi: 10.1042/BSR20130046
17. Habegger KM, Heppner KM, Geary N, Bartness TJ, DiMarchi R, Tschop MH (2010) The metabolic actions of glucagon revisited. Nat Rev Endocrinol 6: 689-697 doi: 10.1038/nrendo.2010.187
18. Heppner KM, Habegger KM, Day J, Pfluger PT, Perez-Tilve D, Ward B, et al. (2010) Glucagon regulation of energy metabolism. Physiol Behav 100: 545-548 doi: 10.1016/j.physbeh.2010.03.019
19. Fukami A, Seino Y, Ozaki N, Yamamoto M, Sugiyama C, Sakamoto-Miura E, et al. (2013) Ectopic expression of GIP in pancreatic β-cells maintains enhanced insulin secretion in mice with complete absence of proglucagon-derived peptides. Diabetes 62: 510-518 doi: 10.2337/db12-0294
20. Hayashi Y, Yamamoto M, Mizoguchi H, Watanabe C, Ito R, Yamamoto S, et al. (2009) Mice deficient for glucagon gene-derived peptides display normoglycemia and hyperplasia of islet α-cells but not of intestinal L-cells. Mol Endocrinol 23: 1990-1999 doi: 10.1210/me.2009-0296
21. Kinoshita K, Ozaki N, Takagi Y, Murata Y, Oshida Y, Hayashi Y (2014) Glucagon is essential for adaptive thermogenesis in brown adipose tissue. Endocrinology 155: 3484-3492 doi: 10.1210/en.2014-1175
22. Kanoski SE, Fortin SM, Arnold M, Grill HJ, Hayes MR (2011) Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4. Endocrinology 152: 3103-3112 doi: 10.1210/en.2011-0174
23. Watanabe C, Seino Y, Miyahira H, Yamamoto M, Fukami A, Ozaki N, et al. (2012) Remodeling of hepatic metabolism and hyperaminoacidemia in mice deficient in proglucagon-derived peptides. Diabetes 61: 74-84 doi: 10.2337/db11-0739
24. Sakamoto E, Seino Y, Fukami A, Mizutani N, Tsunekawa S, Ishikawa K, et al. (2012) Ingestion of a moderate high-sucrose diet results in glucose intolerance with reduced liver glucokinase activity and impaired glucagon-like peptide-1 secretion. J Diabetes Invest 3: 432-440
25. Buteau J (2008) GLP-1 receptor signaling: effects on pancreatic β-cell proliferation and survival. Diabetes Metab 34 Suppl 2: S73-77 doi: 10.1016/S1262-3636(08)73398-6
26. Lee Y, Wang MY, Du XQ, Charron MJ, Unger RH (2011) Glucagon receptor knockout prevents insulindeficient type 1 diabetes in mice. Diabetes 60: 391-397 doi: 10.2337/db10-0426
27. Unger RH, Cherrington AD (2012) Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J Clin Invest 122: 4-12 doi: 10.1172/JCI60016
28. Prentki M, Nolan CJ (2006) Islet β cell failure in type 2 diabetes. J Clin Invest 116: 1802-1812
29. Sachdeva MM, Stoffers DA (2009) Minireview: Meeting the demand for insulin: molecular mechanisms of adaptive postnatal β-cell mass expansion. Mol Endocrinol 23: 747-758 doi: 10.1210/me.2008-0400
30. Mu J, Jiang G, Brady E, Dallas-Yang Q, Liu F, Woods J, et al. (2011) Chronic treatment with a glucagon receptor antagonist lowers glucose and moderately raises circulating glucagon and glucagon-like peptide 1 without severe α cell hypertrophy in diet-induced obese mice. Diabetologia 54: 2381-2391 doi: 10.1007/s00125-011-2217-2
31. Hansotia T, Maida A, Flock G, Yamada Y, Tsukiyama K, Seino Y, et al. (2007) Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. J Clin Invest 117: 143-152
32. Jun LS, Millican RL, Hawkins ED, Konkol DL, Showalter AD, Christe ME, et al. (2015) Absence of glucagon and insulin action reveals a role for the GLP-1 receptor in endogenous glucose production. Diabetes 64: 819-827 doi: 10.2337/db14-1052
33. Lamont BJ, Li Y, Kwan E, Brown TJ, Gaisano H, Drucker DJ (2012) Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice. J Clin Invest 122: 388-402 doi: 10. 1172/JCI42497
34. Omar BA, Andersen B, Hald J, Raun K, Nishimura E, Ahren B (2014) Fibroblast growth factor 21 (FGF21) and glucagon-like peptide 1 contribute to diabetes resistance in glucagon receptor-deficient mice. Diabetes 63: 101-110 doi: 10.2337/db13-0710
35. Ayala JE, Bracy DP, James FD, Burmeister MA, Wasserman DH, Drucker DJ (2010) Glucagon-like peptide-1 receptor knockout mice are protected from high-fat diet-induced insulin resistance. Endocrinology 151: 4678-4687 doi: 10.1210/en.2010-0289
36. Hansotia T, Baggio LL, Delmeire D, Hinke SA, Yamada Y, Tsukiyama K, et al. (2004) Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes 53: 1326-1335
37. Abegg K, Schiesser M, Lutz TA, Bueter M (2013) Acute peripheral GLP-1 receptor agonism or antagonism does not alter energy expenditure in rats after Roux-en-Y gastric bypass. Physiol Behav 121: 70-78 doi: 10.1016/j.physbeh.2013.03.027
38. Bradley DP, Kulstad R, Racine N, Shenker Y, Meredith M, Schoeller DA (2012) Alterations in energy balance following exenatide administration. Appl Physiol Nutr Metab 37: 893-899 doi: 10.1139/h2012-068
39. Knauf C, Cani PD, Ait-Belgnaoui A, Benani A, Dray C, Cabou C, et al. (2008) Brain glucagon-like peptide 1 signaling controls the onset of high-fat diet-induced insulin resistance and reduces energy expenditure. Endocrinology 149: 4768-4777 doi: 10.1210/en.2008-0180
40. Osaka T, Endo M, Yamakawa M, Inoue S (2005) Energy expenditure by intravenous administration of glucagon-like peptide-1 mediated by the lower brainstem and sympathoadrenal system. Peptides 26: 1623-1631
41. Peschechera A, Eckel J (2013) "Browning" of adipose tissue-regulation and therapeutic perspectives. Arch Physiol Biochem 119: 151-160 doi: 10.3109/13813455.2013.796995
42. Auffret J, Viengchareun S, Carre N, Denis RG, Magnan C, Marie PY, et al. (2012) Beige differentiation of adipose depots in mice lacking prolactin receptor protects against high-fat-diet-induced obesity. FASEB J 26: 3728-3737 doi: 10.1096/fj.12-204958
43. Sakamoto T, Takahashi N, Sawaragi Y, Naknukool S, Yu R, Goto T, et al. (2013) Inflammation induced by RAW macrophages suppresses UCP1 mRNA induction via ERK activation in 10T1/2 adipocytes. Am J Physiol Cell Physiol 304: C729-738 doi: 10.1152/ajpcell.00312.2012